Treating FSGS: From Steroids to Dual Endothelin Angiotensin Receptor Antagonists and What Comes Next
Kirk Campbell, MD
Jai Radhakrishnan, MD
The Podocyte Problem: Understanding FSGS
Alessia Fornoni, MD, PhD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Improving Sleep and Mental Health in Patients with CKD-aP
Leonie Kraft, MD
Lucio Manenti, MD, PhD
Quantifying CKD-aP: Tools for Better Care
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD
Is CKD-aP Hiding in Your Dialysis Center?
CKD-aP: Beyond the Surface
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD
Muh Geot Wong, MBBS, PhD
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
Potassium Binders in Practice: Clinical Trial Evidence
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
The Critical Interplay: CKD, HF, and HyperkaleAmia
Javed Butler, MD
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.